{"id":"W3202730600","doi":"10.1016/j.annonc.2021.08.1316","title":"906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Foundation Medicine; Genentech; Merck Sharp and Dohme; Julius Clinical; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; European Society for Medical Oncology; Vifor Pharma; Basilea Pharmaceutica; Astellas Pharma; Eisai; Springworks Therapeutics; Celldex Therapeutics; MacroGenics; Pfizer; Incyte; Moderna; Shionogi; Actuate Therapeutics; BeiGene; Mirati Therapeutics; Agios Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Karyopharm Therapeutics; F. Hoffmann-La Roche; Bayer HealthCare; Sanofi; GlaxoSmithKline; Amgen; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Head and neck; Oncology; Head and neck squamous-cell carcinoma; Basal cell; Head and neck cancer; Internal medicine; Radiation therapy; Cancer; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001369118,0.00007475304,0.0003470808,0.00009755009,0.0000275499,0.000003477825,0.00002912674,0.00004270026,0.00006577513],"category_scores_gemma":[0.0001596442,0.00004738952,0.0000361281,0.0003164731,0.0001151381,0.00004586579,0.00004083062,0.0001008628,4.837988e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001544524,"about_ca_system_score_gemma":0.0001673007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008794796,"about_ca_topic_score_gemma":0.0004759432,"domain_scores_codex":[0.9992134,0.000136687,0.0002429587,0.0001443074,0.0001413681,0.0001212949],"domain_scores_gemma":[0.9992604,0.0001332284,0.0001524094,0.0001312289,0.0002715436,0.00005116546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001691862,0.005418961,0.9773151,0.0006747736,0.00006551639,0.00007586004,0.000844943,0.000008807702,0.001943457,0.0002012781,0.001230634,0.01052877],"study_design_scores_gemma":[0.01377041,0.006729947,0.9577083,0.0002485581,0.0001275021,0.00001526872,0.0004571823,0.0002558393,0.01969226,0.0001565035,0.0007488659,0.0000893633],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962323,0.0002487702,0.000003994325,0.001759813,0.00001235325,0.0001610061,0.00002090435,0.000002446816,0.001558356],"genre_scores_gemma":[0.999066,0.00003339312,0.0001180177,0.0005235625,0.000004772233,0.000005235465,0.00002917208,0.000005634128,0.0002142156],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01960682,"threshold_uncertainty_score":0.1932488,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04584884768537117,"score_gpt":0.3325130936566644,"score_spread":0.2866642459712933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}